

REMARKS

This Amendment is submitted preliminary to the issuance of an Office Action in the present application and in response to the final Official Action of April 9, 2007.

Record is also made of an interview between applicant's representative and the Examiner which took place on July 19, 2007. The Examiner is thanked for his help and assistance as well as for the courtesies extended to Counsel at that time. During the course of the interview, the present application (as well as the companion case Serial No.: 10/816,465) were extensively discussed in light of the final rejection of claims 19-23 in the instant case. During the interview, applicant's representative pointed out to the Examiner that the limitations of claim 23 are not found in the prior art. The Examiner agreed and suggested that if claim 22 would incorporate the limitations of claim 23 the claim would be allowable over the prior art. Accordingly, applicant has drafted a new claim 24 which incorporates the limitations of claim 22 and the language "wherein the vaccine further comprises at least one oligopeptide; wherein the at least one oligopeptide is consisting of the amino acid sequence SEQ ID 3" as suggested by the Examiner.


As a result of the interview, applicant now submits new claim 24 which is drawn up in accordance with the agreement at the interview so as to overcome each and every objection or rejection to the claims as set forth in the Examiner's final Official Action of April 9, 2007, and since claims 19-23 are now canceled.

In view of the above, the presently pending claim 24 in this application is considered patentably differentiated over the prior art of record and believed to be in immediate conditions for allowance. Reconsideration and allowance of the present application are thus respectfully requested.

Should the Examiner consider necessary or desirable any formal changes anywhere in the specification, claims and/or drawing, then it is respectfully requested that such changes be made by Examiner's Amendment, if the Examiner feels this would facilitate passage of the case to issuance. If the Examiner feels

that it might be helpful in advancing this case by calling the undersigned, applicant would greatly appreciate such a telephone interview.

Respectfully submitted,

By: 
Ursula B. Day
Attorney for Applicant
Reg. No. 47,296

Date: August 9, 2007
350 Fifth Avenue
Suite 4714
New York, N.Y. 10118
(212) 244-5500
UBD:af